Value and Reimbursement
Friday, May 31, 2024 03:45 PM - 04:45 PM
Room 212-214
Concurrent Session
Chair
Are you considering your strategy and approach early enough? Do you know what challenges and opportunities lie ahead to ensure C> innovations actually get to those who can benefit in routine clinical practice? The reimbursement landscape globally is complex, with every geography approaching it subtly, if not significantly, differently. In some areas the value proposition translates into pure negotiations, in other countries it can require a full in-depth health economics analysis to enable funding. Add in reference pricing, insurance company rules and requirements, and accountancy limitations around pricing agreements, and it gets even more complicated to secure reimbursement.
This session will unpick some of these topics in more depth and share insights from market access experts with specific experience in the cell and gene arena, with the aspiration that new companies start planning their access strategy in parallel to their phase II/III trials.
- Tania Bubela, BSc (Hons), PhD, JD, FCAHS, FRSC, Simon Fraser University, Canada
- Dean Regier, PhD, University of British Columbia & BC Cancer, Canada
- Brad Groves , B. Arts (Hons), MAP Patient Access, United Kingdom
- Jen (Goldenberg) Klarer, M.Sc.Eng., Partner | Head of Cell & Gene Therapy, The Dedham Group, United States
Are you considering your strategy and approach early enough? Do you know what challenges and opportunities lie ahead to ensure C> innovations actually get to those who can benefit in routine clinical practice? The reimbursement landscape globally is complex, with every geography approaching it subtly, if not significantly, differently. In some areas the value proposition translates into pure negotiations, in other countries it can require a full in-depth health economics analysis to enable funding. Add in reference pricing, insurance company rules and requirements, and accountancy limitations around pricing agreements, and it gets even more complicated to secure reimbursement.
This session will unpick some of these topics in more depth and share insights from market access experts with specific experience in the cell and gene arena, with the aspiration that new companies start planning their access strategy in parallel to their phase II/III trials.
